Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Cardinal Health Inc (CAH) vs Raytheon Technologies Corp (RTX) Price & Performance

Cardinal Health IncTrade
Raytheon Technologies CorpTrade

Price performance (Past 24H)

Key statistics

Cardinal Health Inc vs Raytheon Technologies Corp — how do they compare? Cardinal Health Inc trades at $236.52 (market cap $55.88B), while Raytheon Technologies Corp trades at $220.49 (market cap $301.71B). The key difference: Raytheon Technologies Corp is far larger — about 5.4× Cardinal Health Inc's market cap, and Raytheon Technologies Corp pays the higher dividend (1.3%). Which is the better fit depends on your goals.

CAHRTX
Market Cap
$55.88B$301.71B
Sector
HealthIndustrials
52-Week High
$240.26$224.12
52-Week Low
$146.04$151.75
Enterprise Value
$59.91B$332.26B
Dividend Yield
0.86%1.3%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Cardinal Health Inc

Cardinal Health (CAH) trades at $237.18, up 0.33% on the day, near its 52-week high. The stock shows bullish technical signals with consistent earnings beats, including Q2 2026 EPS of $2.91 versus $2.42 expected. Revenue reached $222.58 billion in 2025, with net income margin improving to 0.67%. Positive sentiment is driven by strong Q4 2026 results and optimistic fiscal 2027 guidance highlighted by Reuters on August 11, 2026.

Outlook remains favorable with analyst consensus price target of $266.43 implying 12% upside. Key opportunities include pharmaceutical segment strength and dividend payments, while risks involve high debt levels and thin profit margins. The bullish analyst stance (54.55% buy ratings) supports growth potential, but investors should monitor cash flow volatility and competitive pressures.

Raytheon Technologies Corp

RTX trades at $224.12, up 0.49% today, near its 52-week high. The stock shows strong technical momentum with bullish moving averages and support at $223. Fundamentally, revenue grew to $88.6B in 2025 with net income of $6.73B, and recent contract wins like the $515M SPY-6 radar award bolster growth prospects. Earnings have consistently beaten estimates, with Q2 2026 EPS of $1.89 exceeding expectations.

The outlook is positive given robust defense spending and operational execution, but valuation multiples like a P/E of 39.41 pose risks if growth slows. Analyst consensus is bullish with a $233.14 price target, though overbought RSI levels suggest near-term consolidation may occur. Key risks include execution delays and macroeconomic pressures on defense budgets.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Cardinal Health Inc

Cardinal Health is a leading pharmaceutical wholesaler, engaged in the sourcing and distribution of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail-order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and McKesson, the three compose well over 90% of the U.S. pharmaceutical wholesale industry. Cardinal Health also supplies medical-surgical products and equipment to healthcare facilities in North America, Europe, and Asia.

Read more on CAH

About Raytheon Technologies Corp

Raytheon Technologies is a diversified aerospace and defense industrial company formed from the merger of United Technologies and Raytheon, with roughly equal exposure as a supplier to commercial aerospace manufactures and to the defense market as a prime and subprime contractor.

Read more on RTX